GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (BOM:544222) » Definitions » Change In Receivables

Akums Drugs and Pharmaceuticals (BOM:544222) Change In Receivables : ₹1,545 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Change In Receivables?

Akums Drugs and Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2024 was ₹-1,222 Mil. It means Akums Drugs and Pharmaceuticals's Accounts Receivable increased by ₹1,222 Mil from Mar. 2024 to Sep. 2024 .

Akums Drugs and Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-32 Mil. It means Akums Drugs and Pharmaceuticals's Accounts Receivable increased by ₹32 Mil from Mar. 2023 to Mar. 2024 .

Akums Drugs and Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2024 was ₹9,493 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Akums Drugs and Pharmaceuticals's Days Sales Outstanding for the six months ended in Sep. 2024 was 84.42.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akums Drugs and Pharmaceuticals's liquidation value for the six months ended in Sep. 2024 was ₹4,426 Mil.

Akums Drugs and Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Change In Receivables Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Change In Receivables
361.48 -3,717.75 349.11 -32.32

Akums Drugs and Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Change In Receivables Get a 7-Day Free Trial -673.72 1,022.83 -2,799.53 2,767.21 -1,221.86

Akums Drugs and Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹1,545 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals  (BOM:544222) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akums Drugs and Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=9493.12/20522*91
=84.42

2. In Ben Graham's calculation of liquidation value, Akums Drugs and Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Akums Drugs and Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=8242.89-14234.24+0.75 * 9493.12+0.5 * 6595.96
=4,426

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (BOM:544222) » Definitions » Change In Receivables
Comparable Companies
Traded in Other Exchanges
AKUMS:India
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Website
https://www.akums.in
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines